Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02239614 · ClinicalTrials.gov registry record · Phase 1

TDENV PIV and LAV Dengue Prime-boost Strategy

A Phase 1 study of Dengue, sponsored by U.S. Army Medical Research and Development Command.

Completed
Registry status
Phase 1
Development phase
80
Enrollment target
1
Study location

NCT02239614: Completed Phase 1 study of Dengue, sponsored by U.S. Army Medical Research and Development Command.

NCT02239614 is a Phase 1 study of Dengue that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 80 participants, below the 3,972-participant average among 9 other Dengue trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02239614, a Phase 1 study of Dengue, has completed, sponsored by U.S. Army Medical Research and Development Command.

COMPLETED
Registry status
Phase 1
Development phase
80 participants
Enrollment target
1
Study location

Study Summary

The potential synergistic effect of administering 2 dengue vaccine candidates that were previously shown to be safe and immunogenic in humans will be evaluated in this study. A prime-boost study of tetravalent dengue virus purified inactivated vaccine (TDENV-PIV) with alum and tetravalent dengue live attenuated virus (TDENV-LAV) vaccine Formulation 17 (F17) will gather data to help better understand the human immune response to dengue vaccination and infection.

Conditions Studied

Dengue

Interventions

  • BIOLOGICAL TDENV-LAV
  • BIOLOGICAL TDENV-PIV 4 µg + alum adjuvant

Study Locations (1)

Maryland

  • Clinical Trials Center, Walter Reed Army Institute of Research (CTC, WRAIR) - Silver Spring

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2014-12
Est. Completion 2017-02-17
Phase Phase 1
U.S. Army Medical Research and Development Command

77 total trials

What the finished NCT02239614 record still lists

NCT02239614 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 3,972-participant average among 9 other Dengue trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Dengue appearing as the primary indexed condition, and to 2 interventions - of which TDENV-LAV is the first listed.

NCT02239614 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT02239614 about?

NCT02239614 is a clinical study titled "TDENV PIV and LAV Dengue Prime-boost Strategy". The potential synergistic effect of administering 2 dengue vaccine candidates that were previously shown to be safe and immunogenic in humans will be evaluated in this study. A prime-boost study of tetravalent dengue virus purified inactivated vaccine (TDENV-PIV) with alum and tetravalent dengue liv...

What is the current status of trial NCT02239614?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2014-12. Estimated completion is 2017-02-17.

What conditions does trial NCT02239614 study?

This clinical trial studies the following conditions: Dengue.

What interventions are being tested in trial NCT02239614?

The interventions under investigation include: TDENV-LAV (BIOLOGICAL), TDENV-PIV 4 µg + alum adjuvant (BIOLOGICAL).

Who is sponsoring clinical trial NCT02239614?

This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02239614 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Dengue

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02239614's enrollment target sits among peer trials

80 4th of 9 higher than 6 of 9 other Dengue trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Dengue trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT02239614, the US trial registry maintained by the National Library of Medicine. NCT02239614 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.